ICON PLC (NASDAQ:ICLR) target bumped up to $87.00, released a ratings update today by Zacks Investment Research
- Updated: September 28, 2016
ICON PLC (NASDAQ:ICLR) had its price target upped to $87.00 by Zacks Investment Research in a report released 09/28/2016. The bumped up target suggests a potential upside of 0.13% from the company's most recent stock price.
Previously on 06/21/2016, Credit Suisse released a statement about ICON PLC (NASDAQ:ICLR) increased the target price from $0.00 to $80.00. At the time, this indicated a possible upside of 0.23%.
Just yesterday ICON PLC (NASDAQ:ICLR) traded -0.01% lower at $77.28. ICON PLC’s 50-day moving average is $76.21 and its 200-day moving average is $71.84. The last stock price is up 7.57% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 302,268 shares of ICLR traded hands, down from an average trading volume of 404,188
Recent Performance Chart
ICON PLC has 52 week low of $62.31 and a 52 week high of $79.61 with a PE ratio of 17.86 and has a market capitalization of $0.
In addition to Zacks Investment Research reporting its stock price target, a total of 11 brokerages have issued a ratings update on the company. The average stock price target is $77.36 with 3 brokerages rating the stock a strong buy, 4 brokerages rating the stock a buy, 7 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 2 brokerages rating the stock a sell.
Brief Synopsis On ICON PLC (NASDAQ:ICLR)
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. Its services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. The Company's information systems offerings include ICONIK, Firecrest, ADDPLAN, AptivAdvantage and Aptiv Insite. It conducts various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial. The Company offers clinical development services, including investigator recruitment, patient registries, outcomes research, clinical data management, immunoassay development and others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.